Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE).

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Designing Consent Processes for Research With Older Adults Who May Lack Decisional Capacity: A Guide for Investigators.

Journal of the American Geriatrics Society·2026
Same author

Four Common Beliefs About Patient Memory Evaluations: Who Has Them and What Modifies Them?

American journal of Alzheimer's disease and other dementias·2026
Same author

Expert consensus on communicating tau PET results to persons living with MCI or dementia: Findings from a modified Delphi study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Ambiguous Loss.

JAMA·2026
Same author

Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress.

JAMA network open·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Megan Zhang1, Abigail Perelman2, Cameron Coykendall2

  • 1University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

血p-tau181测试显著提高了临床医生对诊断阿尔茨海默病 (AD) 的信心. 这种血液检测有助于重新分类诊断,并指导患者管理,改善早期和准确的阿尔茨海默病检测.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物研究 生物标志物研究
  • 诊断医学 诊断医学

背景情况:

  • 早期和准确的阿尔茨海默病 (AD) 诊断对于及时的护理至关重要.
  • 基于血液的生物标志物,如血p-tau181,为传统诊断方法提供了可访问的替代方案.
  • 血p-tau181对临床决策的影响需要进一步研究.

研究的目的:

  • 评估血p-tau181测试结果如何影响诊断,临床医生的信心和患者管理.
  • 评估血p-tau181作为存储中心设置中的诊断工具的实用性.
  • 了解血p-tau181在区分AD和非AD疾病中的作用.

主要方法:

  • 使用了LucentAD血p-tau181测试,具有定义的灵敏度和特异性.
  • 招募的患者有轻度认知障碍或痴呆症,没有先前的AD生物标志物诊断.
  • 收集的临床医生调查数据测试前和后,补充了图表抽象.

主要成果:

  • 血p-tau181测试导致临床医生的诊断信心显著增加 (p < 0.001).
  • 测试结果为AD和非AD条件的诊断重新分类提供了信息.
  • 结果的披露促使药物调整,新的咨询和进一步的诊断测试,包括腰部穿刺和PET扫描在某些情况下.

结论:

  • 血p-tau181检测是提高阿尔茨海默病诊断信心的宝贵工具.
  • 该测试有效地为临床决策提供信息,有助于区分AD和其他神经退行性疾病.
  • 这种血液生物标志物有助于更准确和及时的诊断,可能改善患者护理途径.